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Background: The aim of this study was to evaluate the associations between phase angle (PhA), sarcopenia, and
the length of stay (LOS) in the coronary intensive care unit (ICU) in patients with non-ST acute coronary syndrome
(NSTE-ACS).
Methods: This was a prospective observational study that evaluated 80 patients with NSTE-ACS over the age of
18 years, admitted to the ICU from January to June 2014. Upon admission, the patients’ demographic information
was recorded. Handgrip strength and bioelectrical impedance analysis (BIA) were performed, and blood samples
were taken within the first 72 h of admission. All of the patients were followed during their ICU stays.
Results: We evaluated 80 patients, five were excluded due to impossibility of assessing handgrip strength, and
seven patients were not subjected to BIA. Thus, 68 patients with a mean age of 63.3 ± 13.1 years were included in
the analysis. Among these patients, 60.1% were male, 27.9% of the patients had sarcopenia, 8.8% had LOSs ≥8 days,
and median phase angle was 6.5 (6.1–7.3)°. Multiple logistic regression adjusted for age and gender revealed that
PhA was not associated with the presence of sarcopenia. Additionally, PhA (OR 0.337; CI 95% 0.118–0.961; p = 0.04)
but not sarcopenia (OR 0.517; CI 95% 0.055–4.879; p = 0.56) was associated with an increased LOS.
Conclusions: PhA is associated with LOS in patients with NSTE-ACS. Additionally, there was no association between
PhA and sarcopenia.
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Currently, cardiovascular diseases are the major cause of
death worldwide [1, 2]. Acute coronary syndrome is the
most common cause of cardiovascular morbidity and
mortality [1, 2]. Acute coronary syndrome is a term that
refers to a spectrum of conditions that are compatible
with acute myocardial ischemia and/or infarction. Acute
coronary syndrome is classified as ST elevation myocar-
dial infarction or non-ST elevation acute coronary* Correspondence: berthafurlan@fmb.unesp.br
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vided into non-ST elevation myocardial infarction and
unstable angina [1]. More than 625000 patients present
with NSTE-ACS each year in the United States, and the
in-hospital mortality is approximately 5–13% within
6 months [1, 2]. The 4-year mortality rate for NSTE-
ACS is twofolds greater than that of ST-elevation myo-
cardial infarction. This difference might be attributable
to the fact that NSTE-ACS patients are older and have
more comorbidities [3].
With the aging process, several alterations in organs
and systems can lead to decreased strength and func-
tionality [4]. Age-related decline in skeletal muscle mass
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populations, and the direct costs of this condition in the
United States exceed $18.5 billion annually [5]. Sarcope-
nia increases the risk for adverse outcomes, such as
physical disability, poor quality of life, and death [4, 5].
Sarcopenia is associated with poor outcomes in patients
who undergo major surgery and transplantation, patients
with cancer, hospitalized patients, and elderly residents
of nursing homes [6]. However, the role of sarcopenia in
acute coronary syndrome outcomes has not yet been
studied.
Currently, the diagnosis of sarcopenia is based on
low whole-body or appendicular fat-free masses in
combination with poor physical functioning [7]. There
are several techniques for assessing skeletal muscle
mass, including dual energy X-ray absorptiometry,
magnetic resonance imaging, and bioelectrical imped-
ance analysis (BIA). In addition to body composition
assessment, one of the most clinically established im-
pedance parameters is the phase angle (PhA) [7]. The
PhA is estimated as the direct ratio between the re-
sistance and reactance and has been used as a prog-
nostic tool in several clinical situations, such as
malnutrition and cancer [7, 8]. Basile et al. showed
that the PhA in elderly patients is inversely related to
muscle mass and strength and can be used to identify
elderly patients who are at risk for sarcopenia [7].
The relationships between PhA, sarcopenia, and out-
comes in hospitalized patients with NSTE-ACS have not
yet been evaluated. The diagnosis of sarcopenia and
lower values of PhA could identify patients that need a
close monitoring and a more aggressive treatment. Thus,
the aim of this study was to evaluate the associations be-
tween phase angle, sarcopenia, and the length of stay
(LOS) in the ICU among patients with NSTE-ACS.
Methods
The present study was conducted according to the
guidelines laid down in the Declaration of Helsinki, and
all procedures involving human patients were approved
by the Ethics Committee of the Botucatu Medical School
(protocol number: 4213–2012). Written informed con-
sent was obtained from all patients. The Fisher and Belle
formula was used to estimate the sample size based on
the following variables: a prevalence of sarcopenia in the
general population of 1 to 33%, the 95% confidence
interval, and a 10% sample error [5]. The result was a
sample size of 62 patients.
In total, 80 patients with non-ST acute coronary syn-
drome over the age of 18 years who were admitted to
the coronary intensive care unit from January to June of
2014 were prospectively evaluated. The exclusion criteria
were pregnancy, valve disease, congenital cardiomyop-
athy, and corticosteroid use.Upon admission, the patients’ demographic informa-
tion, including age, gender, and diagnosis were recorded.
Handgrip strength and BIA were assessed, and blood
samples were collected for serum biochemistry within
the first 72 h of admission. All of the patients were
followed during their ICU stays, and the LOSs were
recorded.
Sarcopenia was defined as a decreased skeletal
muscle mass index (♀ < 6.76 and ♂ < 10.76 kg/m2) as-
sociated with a reduced handgrip strength (♀ < 20
and ♂ < 30 kg). The skeletal muscle mass index was
calculated according to the following formula using the
BIA data: SMI (kg/m2) = {[(height2/resistance*0.401) + (gen-
der*3825) + (age*−0.071)] + 5102}/height2, where the height
was in centimeter, the resistance was in ohms, gender was
coded as men = 1, and woman = 0, and age was in years [4].
Non-ST acute coronary syndrome was defined as the
presence of ischemic chest pain (retrosternal area with
radiation to either or both of the arms, neck or jaw) with
at least one of the following features: occurring at rest
or with minimal exertion lasting ≥ 10 min, new onset or
increased exertional dyspnea, the absence of ST eleva-
tion on an electrocardiogram, and with or without
troponin increase [1].
LOS stay was categorized as less than 8 days or ≥ 8 days
[1]. The definition of diabetes mellitus was based on
clinical features, and a fasting glucose level of at least
126 mg/dL on two separate occasions or ongoing disease
treatment. Systemic hypertension was defined by a sys-
tolic blood pressure greater than 140 mmHg and/or a
diastolic blood pressure greater than 90 mmHg or on-
going disease treatment. Renal disease was defined as
creatinine clearance < 60 ml/min/1.73 m2 on ICU admis-
sion calculated by Cockcroft-Gault formula.
Handgrip strength
Handgrip strength was measured as previously described
[9]. Briefly, a standard adjustable handle (TEC-60; Tech-
nical Products; Clifton, NJ, USA) was used. All of the
measurements were performed with the non-dominant
hand, with the elbow supported on the bed, and with a
trained examiner administering all of the tests. The sub-
jects performed a maximum of three attempts for each
measurement, and the best performance of these tests
was recorded. During the testing, the participant was
strongly encouraged to exert the maximum possible
force. One minute rests were given between each at-
tempt to minimize fatigue effects.
Laboratory data analysis
The total serum levels of creatine phosphokinase (CK),
creatine phosphokinase-MB (CK-MB), sodium, potas-
sium, creatinine, and urea were measured using the dry
chemistry method (Ortho-Clinical Diagnostics VITROS
Table 1 Demographic, clinical, and laboratory data of the 68
patients with non-ST acute coronary syndrome according to the
length of ICU stay
Variables Length of ICU stay P value
<8 days (n = 62) ≥8 days (n = 6)
Age (years) 62.5 ± 13.0 70.8 ± 12.3 0.14
Male, % (no) 59.7 (37) 66.7 (4) 1.00
Hypertension, % (no) 74.2 (46) 66.7 (4) 0.65
Diabetes, % (no) 43.5 (27) 50.0 (3) 1.00
Renal disease, % (n°) 29.0 (18) 50.0 (3) 0.36
Tobacco smoke, % (n°) 27.4 (17) 33.3 (2) 1.00
Diagnosis, % (no)
Non-ST MI 35.5 (22) 66.7 (4) 0.27
HRUA 48.4 (30) 33.3 (2)
IRUA 16.1 (10) 0 (0)
SMI, (kg/m2) 8.65 ± 1.50 8.73 ± 1.79 0.90
Handgrip strength, (kg) 28.0 (22.0–32.0) 23.0 (12.5–37.3) 0.57
ASA, % (n°) 96.8 (60) 100.0 (6) 1.0
ACEi, % (n°) 71.0 (44) 66.7 (4) 1.0
ARB, % (n°) 14.5 (9) 0 (0) 0.59
Clopidogrel, % (n°) 95.2 (59) 83.3 (5) 0.25
Clexane, % (n°) 83.4 (52) 100.0 (6) 0.59
B-Blockers, % (n°) 72.6 (45) 66.7 (4) 0.64
Hematocrit, (%) 42.5 (38.1–44.7) 41.9 (38.8–42.3) 0.30
CK, (U/L) 116 (73.0–202) 56.5 (38.0–111) 0.03
CK-MB, (U/L) 19.0 (12.0–27.0) 13.0 (6.22–19.0) 0.16
Troponin, (ng/ml) 0.02 (0.01–0.51) 0.30 (0.02–0.45) 0.52
Creatinine, (mg/dL) 0.9 (0.8–1.1) 1.1 (0.8–1.6) 0.53
Urea, (mg/dL) 36.0 (28.0–48.0) 49.5 (42.3–67.3) 0.046
Phase angle, (°) 6.6 (6.1–7.5) 5.5 (4.2–6.9) 0.048
25 (OH) vitamin D, (ng/ml) 19.0 (15.2–21.9) 17.2 (7.1–22.1) 0.32
Sarcopenia, % (n°) 27.4 (17) 33.3 (2) 1.00
The data are expressed as medians (including the lower and upper quartiles)
SMI skeletal muscle mass index, ACEi angiotensin-converting enzyme inhibitor,
ARB angiotensin II receptor blocker, ASA acetylsalicylic acid, CK creatine
phosphokinase, CK-MB creatine phosphokinase-MB, HRUA high risk unstable
angina, IRUA intermediate risk unstable angina
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were measured every 6 h after ICU admission, and the
highest levels were recorded. Troponin I was measured
using the immunoenzymatic method. Hemograms were
acquired with a Coulter STKS hematological autoanaly-
zer. The serum concentrations of 25(OH) vitamin D
were assessed by high-performance liquid chroma-
tography (HPLC; Immundiagnostik AG, Bensheim,
Germany) according to a previously described
method [10]. The assay sensitivity was 2.5 μg/L, and
the coefficient of variation was < 7% [10].
Bioelectrical impedance analysis
BIA was measured using tetrapolar and single-frequency
equipment (Biodynamic-450, 800 μA; 50 kHz) and ap-
plied to the skin using adhesive electrodes with the sub-
ject lying in the supine position. All measurements were
performed in the morning by the same researcher. The
phase angle derived from the BIA was determined as
previously described, and its values were calculated as
follows: phase angle = (arc tangent reactance/resistance *
(180°/π)) [11]. The skeletal muscle mass index calcula-
tion has been described previously.
Statistical analysis
The data are expressed as the means ± SDs or medians
(including the lower and upper quartiles). The statistical
comparisons between groups for continuous variables
were performed using Student’s t tests for parameters
that were normally distributed. For data that were not
normally distributed, the comparisons between groups
(length of ICU stay < 8 days or ≥ 8 days; sarcopenia yes
or no) were made using the Mann-Whitney test. Fisher’s
tests or χ2 tests were used for all categorical data. We
also performed multiple logistic regression analyses that
were adjusted for age and gender to evaluate the associa-
tions of phase angle, sarcopenia, skeletal muscle mass
index, and handgrip strength with the length of ICU stay
(≥8 days). The data analyses were performed using
SigmaPlot software for Windows v12.0 (Systat Software
Inc., San Jose, CA, USA). The significance level was 5%.
Results
In total, 80 patients were evaluated, but five were ex-
cluded because they could not complete the handgrip
strength test, and seven were excluded because they
were not submitted to BIA testing within 72 h. Thus, 68
patients with a mean age of 63.3 ± 13.1 years were in-
cluded in the analysis. Among these patients, 60.1% were
male, 27.9% of the patients had sarcopenia, and the me-
dian PhA was 6.5 (6.1–7.3)°. The median LOS was 4
(3–5) days, and 8.8% of the patients had LOSs ≥ 8 days.
No patients died during their ICU stays. The greatest
proportion of patients had high-risk unstable angina(47.1%) followed by non-ST myocardial infarction
(38.2%) and intermediate risk unstable angina (14.7%).
The demographic, clinical and laboratorial data ac-
cording to LOS are listed in Table 1. The patients with
lengths of ICU stays ≥ 8 days exhibited higher urea and
lower CK and phase angle values. In Table 2, the pa-
tients’ characteristics are listed according to the presence
of sarcopenia. The patients with sarcopenia were older,
and the majority was male. Additionally, the patients
with sarcopenia exhibited lower handgrip strength and
phase angle values. There was no difference in vitamin
D serum levels in the patients with and without
Table 2 Demographic, clinical, and laboratory data of the 68
patients with non-ST acute coronary syndrome according to the
presence of sarcopenia
Variables Sarcopenia P value
No (n = 49) Yes (n = 19)
Age (years.) 59.8 ± 12.1 72.3 ± 11.4 <0.001
Male, % (no) 49.0 (24) 89.5 (17) 0.005
Hypertension, % (no) 71.4 (35) 78.9 (15) 0.75
Diabetes, % (no) 38.8 (19) 57.9 (11) 0.25
Renal disease, % (n°) 28.6 (14) 36.9 (7) 0.71
Tobacco smoke, % (n°) 32.7 (16) 15.8 (3) 0.28
Diagnosis, % (no)
Non-ST MI 32.7 (16) 52.6 (10) 0.31
HRUA 51.0 (25) 36.9 (7)
IRUA 16.3 (8) 10.5 (2)
SMI, (kg/m2) 8.71 ± 1.55 8.52 ± 1.42 0.65
Handgrip strength, (kg) 28.7 ± 9.47 23.2 ± 5.22 0.02
ASA, % (n°) 98.0 (48) 94.7 (18) 1.0
ACEi, % (n°) 71.4 (35) 68.4 (13) 0.81
ARB, % (n°) 12.2 (6) 15.8 (3) 0.69
Clopidogrel, % (n°) 93.9 (46) 94.7 (18) 0.25
Clexane, % (n°) 91.8 (45) 68.4 (13) 0.05
β-Blockers, % (n°) 71.4 (35) 73.7 (14) 0.53
Hematocrit, (%) 42.5 (37.6–44.6) 41.8 (40.4–44.8) 1.00
CK, (U/L) 112 (62.0–170) 98.0 (56.3–414) 0.86
CK-MB, (U/L) 18.0 (11.3–24.8) 20.0 (12.0–36.3) 0.38
Troponin, (ng/ml) 0.02 (0.01–0.36) 0.18 (0.01–0.86) 0.32
Creatinine, (mg/dL) 0.9 (0.8–1.1) 0.9 (0.7–1.1) 0.52
Urea, (mg/dL) 36.0 (28.0–48.8) 38.0 (30.0–50.0) 0.95
Phase angle, (°) 6.8 (6.2–7.8) 6.0 (5.3–6.5) 0.004
25 (OH) vitamin D, (ng/ml) 19.0 (15.1–22.0) 18.9 (13.8–21.4) 0.52
LOS ≥8 days, % (n°) 8.2 (4) 10.5 (2) 1.00
The data are expressed as mean ± SD or medians (including the lower and
upper quartiles)
SMI skeletal muscle mass index, ACEi angiotensin-converting enzyme inhibitor, ARB
angiotensin II receptor blocker, ASA acetylsalicylic acid, CK creatine phosphokinase,
CK-MB creatine phosphokinase-MB, LOS length of ICU stay, HRUA high risk unstable
angina, IRUA intermediate risk unstable angina
Table 4 Multiple logistic regression analyses for the prediction
of a length of ICU stay ≥8 days
Odds ratio 95% confidence interval P value
Phase angle 0.328 0.126–0.853 0.02
Phase anglea 0.337 0.118–0.961 0.04
Sarcopenia 1.324 0.222–7.901 0.76
Sarcopeniaa 0.517 0.055–4.879 0.56
SMI 1.037 0.591–1.820 0.899
SMIa 1.214 0.611–2.409 0.580
Handgrip strength 0.966 0.874–1.068 0.502
Handgrip strengtha 0.968 0.843–1.112 0.648
SMI skeletal muscle mass index
aAdjusted by age and gender
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ceived adequate treatment.
As shown in Table 3, the phase angle was not associ-
ated with the presence of sarcopenia even after adjusting
for age and gender (OR: 0.812; CI 95%: 0.538–1.225; p =Table 3 Multiple logistic regression analyses for the prediction
of sarcopenia
Odds ratio 95% confidence interval P value
Phase angle 0.690 0.449–1.058 0.09
Phase anglea 0.812 0.538–1.225 0.32
aAdjusted by age and gender0.32). The multiple logistic regression analysis that was
adjusted for age and gender (Table 4) revealed that the
phase angle (OR: 0.337; CI 95%: 0.118–0.961; p = 0.04) but
not sarcopenia (OR: 0.517; CI 95%: 0.055–4.879; p = 0.56)
was associated with a higher LOS. The skeletal muscle
mass index and handgrip strength were also not associ-
ated with LOS. For each one-degree increase in PhA, the
likelihood of a longer LOS decreased by almost threefolds.
Discussion
The aim of this study was to evaluate the associations
between PhA, sarcopenia, and LOS in patients with
NSTE-ACS. The diagnosis of sarcopenia and lower values
of PhA could identify patients that need a close monitor-
ing and a more aggressive treatment. However, only PhA
was associated with LOS in these patients. Additionally,
there was no association between PhA and sarcopenia.
Due to the importance of acute coronary syndrome, the
identification of modifiable risk factors that could help to
improve outcomes is urgent. Sarcopenia is associated with
adverse clinical outcomes in several diseases; however, the
association between sarcopenia and acute coronary syn-
drome had not yet been evaluated [6, 12, 13].
It is also important to consider that the characteris-
tics of sarcopenia are included in frailty diagnoses [4].
Thus, most frail older people also exhibit sarcopenia
[4]. There are several mechanisms involved in the on-
set and progression of sarcopenia, such protein syn-
thesis, neuromuscular integrity, muscle fat content
and hormonal changes including changes in vitamin
D status [4, 14]. In the present study, the prevalence
of sarcopenia among the patients with NSTE-ACS
was the same as that described for the general popu-
lation. Additionally, as we expected, the patients with
sarcopenia were older and exhibited lower handgrip
strengths than the patients without this condition.
Although our objective was not to evaluate the asso-
ciation between sarcopenia and vitamin D status, it is
interesting that the vitamin D serum levels were not
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ciency has been associated with muscle strength re-
ductions and increased numbers of falls in older
people [15]. Visser et al. reported that older adults
with vitamin D serum levels below than 25 nmol/L
exhibit decreased skeletal muscle mass and strength
[16]. In this study, the acute phase response due to
NSTE-ACS could have influenced the vitamin D
serum levels. Additionally, different cutoffs values for
identifying vitamin D deficiencies might also explain
these differences.
Regarding the length of hospital stay, Gariballa and
Alessa reported that the length of hospital stay was lon-
ger in patients with sarcopenia among a cohort of 432
hospitalized older patients [17]. Additionally, Cawthon
et al. reported that in adults aged 70 to 80 years, low
muscle density and grip strength were associated with
greater risks of hospitalization [18]. It is also interesting
that increases in the length of hospital stay worsen sar-
copenia, which creates a vicious cycle of disease severity
and increases in the length of hospital stay and re-
hospitalization rate [19]. However, in our study, the
presence of sarcopenia did not influence the LOS.
The association between sarcopenia and PhA has also
been evaluated. In a recent study, the relationships of
PhA with muscle mass and strength were investigated in
207 elderly participants who were admitted for multidi-
mensional geriatric evaluation [7]. The authors found
that PhA was inversely related to muscle mass and
strength in elderly subjects [7]. Wilhelm-Leen et al. also
revealed that lower PhAs were associated with frailty
and mortality in 4667 older adults [20]. However, there
was no association between PhA and sarcopenia in our
study. The reason that this relationship was not ob-
served in our study remains to be elucidated.
In addition to the calculation of the PhA, BIA is typic-
ally used to estimate body composition and skeletal
muscle mass. BIA is a non-invasive method that mea-
sures the opposition of the body to alternating currents
consisting of both resistance and reactance [21]. The
reactance arises from the cell membranes, and the resist-
ance arises from the extra- and intracellular fluids [21].
BIA divides the body into two compartments, i.e., fat-
free mass and fat mass. The fat-free mass includes vis-
ceral proteins, bone mineral content, and intra- and
extracellular water. Thus, there are a large number of
BIA equations in the literature for predicting fat-free
mass [8]. The formula that we used to estimate skeletal
muscle mass is that of the European Consensus of Sar-
copenia in Older Adults [4]. Other techniques for asses-
sing skeletal muscle can be used including dual energy
X-ray absorptiometry and magnetic resonance imaging;
however, BIA is a portable, easy-to-use and inexpensive
method [21].The PhA is estimated as the ratio between resistance
and reactance. The relationship between these factors
reflects different electrical properties of tissues that are
affected in different manners by disease, hydration and
nutritional status [21]. Additionally, due to its close cor-
relations with nutritional and functional statuses, PhA
has been used to predict outcomes in different clinical
situations. Authors have found that low PhA values pre-
dict worse outcomes in patients with renal insufficiency,
liver cirrhosis, and surgical patients [22–24]. However,
PhA had not previously been evaluated in patients with
NSTE-ACS. In our study, the patients with higher PhA
values were associated with lower LOSs even after
adjusting for age and gender. For each one-degree in-
crease in PhA, the likelihood of a longer LOS decreased
by almost threefolds. Therefore, PhA could be incorpo-
rated into clinical practice as a tool for predicting the
LOSs of patients with NSTE-ACS.
It is important to consider some limitations of our
study. Our study included a small sample size and pa-
tients from a unique medical center. We also used
single-frequency BIA to determine the reactance and re-
sistance and to evaluate the skeletal muscle mass index.
Despite these limitations, this is the first study to evalu-
ate the relationship between PhA and sarcopenia in pa-
tients with NSTE-ACS.
Conclusions
In conclusion, PhA, but not sarcopenia, is associated
with the lengths of ICU stay in patients with NSTE-
ACS. Additionally, there was no association between
PhA and sarcopenia.
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